Julie R. Brahmer

1. Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies
   2008/05/20 by Julie R. Brahmer, Suzanne L. Topalian, Ira Wollner +7 · 1 citation
   Medicine · Biochemistry, Genetics and Molecular Biology · #Cancer Immunotherapy and Biomarkers #CAR-T cell therapy research #Cancer Genomics and Diagnostics
2. Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
   2010/06/01 by Julie R. Brahmer, Charles G. Drake, Ira Wollner +17 · 1 citation
   Medicine · Immunology and Microbiology · #Cancer Immunotherapy and Biomarkers #Immunotherapy and Immune Responses #CAR-T cell therapy research